Healthcare / Drug Manufacturers - Specialty & GenericASX
$2.41
+0.01 (+0.42%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $12.3M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
65/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$131M
P/E
13.4x
↓EV/EBITDA
6.6x
↓ROE
18.6%
↑Gross Margin
61.2%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+11.7%
FCF CAGR
+81.9%
FCF margin
17.0%
FCF / Net income
1.52x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $93.3M · net income $10.4M · FCF $15.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $93.3M | $93.3M | $79.5M | $74.2M | $66.9M |
| Net Income | $10.4M | $10.4M | $8.8M | $9.1M | $7.1M |
| EBITDA | $15.8M | $15.8M | $13.5M | $13.1M | $11.4M |
| EPS | 0.18 | 0.18 | 0.16 | 0.17 | 0.13 |
| Gross Margin | 61.2% | 61.2% | 59.4% | 58.1% | 59.4% |
| Operating Margin | 15.1% | 15.1% | 14.7% | 16.0% | 16.0% |
| Net Margin | 11.2% | 11.2% | 11.0% | 12.2% | 10.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.04 | 0.04 | 0.01 | 0.01 | 0.02 |
| Current Ratio | 2.73 | 2.73 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $15.9M | $15.9M | $6.0M | $12.3M | $2.6M |
| Returns | |||||
| ROE | 18.6% | 18.6% | 16.8% | 20.9% | 19.4% |
| Valuation | |||||
| P/E | 13.39 | 13.39 | 12.18 | 11.33 | 10.33 |
| EV/EBITDA | 6.58 | 6.58 | 5.86 | 4.53 | 5.11 |
| P/B | 2.44 | 2.44 | 2.04 | 2.37 | 2.00 |
| Growth & Yield | |||||
| Revenue Growth | 17.3% | 17.3% | 7.2% | 10.9% | — |
| EPS Growth | 14.9% | 14.9% | -3.8% | 26.5% | — |
| Dividend Yield | 5.8% | 5.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
5.2%
EPS terminal req.
$0.21
Spread vs growth
9.7%
5Y implied EPS CAGR
7.1%
EPS terminal req.
$0.26
Spread vs growth
7.8%
10Y implied EPS CAGR
8.5%
EPS terminal req.
$0.42
Spread vs growth
6.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+31.3%
Start / end P/E
12.0x → 13.1x
EPS bridge
0.16 → 0.18
Residual
+1.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.